Modulation of Hyperandrogenic Anovulation Through Fenugreek Seeds

May 22, 2026 updated by: Maria Aslam, University of Lahore

Modulation of Hyperandrogenic Anovulation Through Fenugreek(Trigonella Foenum Graecum L.) Seeds Among Young Females

Hyperandrogenic anovulation is a common gynecological illness that impacts the ovaries, vagina and uterus. According to Statistics, in Pakistan 17.6% of individuals seeking treatment at infertility clinics were found to be affected by hyperandrogenic anovulation. Studies indicate that fenugreek seeds have the potential to improve insulin sensitivity, control hormone levels, namely the increased androgens linked to hyperandrogenic anovulation, and promote ovulation, a process commonly interrupted in individuals with hyperandrogenic anovulation. In order to create a therapy plan that is both affordable and easily accessible for women who suffer from hyperandrogenic anovulation, this study aims to determine the therapeutic efficacy of fenugreek seed powder in reducing symptoms related to the illness. Furthermore, it aims to increase knowledge on the extensive utilization of fenugreek seed powder as a natural treatment for hyperandrogenic anovulation.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

  • To collect data, written consent was obtained from the hospital and university administration.

  • After receiving signed informed consent, the data were collected.

    1. Screening: The participants who meet the study inclusion criteria were enrolled and FSH/LH, Insulin resistance or lipid profile samples were taken by the hospital lab assistant. The participants will be requested not to alter their routine physical activity.
    2. Allocation: Following screening, participants were divided evenly into three groups: experimental group (1, 2) and one control group. The participants received different dosage in different experimental groups of fenugreek seeds powder) c.Follow up: A systematic communication plan will be developed in order to follow up with participants on their daily consumption of the suggested fenugreek powder through telephonic conversations. For continuous assistance there was a WhatsApp group set up where members may ask issues and get help associated with hyperandrogenic anovulation. The follow up for patients were conducted every month; baseline and after 60 days. Appointments for follow-up exams were made in order to track developments, anthropometric measurements were calculated every follow up and modify the dosage as necessary. The baseline and post study test were compared to test the hypothesis.

Study Type

Interventional

Enrollment (Actual)

70

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
      • Lahore, Pakistan, 54000
        • Punjab medical center, jail road, Lahore

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Female have been BMI more than 25
  • Patients with irregular periods or hormonal imbalance
  • Patients with age 15 to 25 years of young females

Exclusion Criteria:

  • Pregnant & Lactating Women
  • Any history of allergic reaction to fenugreek seeds
  • Severe gastrointestinal disorders like crohn's disease
  • People with liver or kidney issue

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control group
• Control group (G0): Participants were only subjected to use Glucophage 500mg 30 minutes before breakfast prescribed by doctor.
Drug: Control
Participants were only subjected to use Glucophage 500mg 30 minutes before breakfast for the duration of 02 months.
Experimental: fenugreek seeds low dose
3gram/ half teaspoon fenugreek seeds powder
Dietary supplement: Fenugreek seeds (G1):
Participants were advised to take 3g/half teaspoon fenugreek seeds powder 30 minutes before breakfast for the duration of 02 month.
Experimental: Fenugreek seeds high dose
6gram/ one teaspoon fenugreek seeds
Dietary supplement: Fenugreek seeds (G2)
Participants were advised to take 6g/one teaspoon fenugreek seeds powder 30 minutes before breakfast for the duration of 02 months.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
FSH/LH Test
Time Frame: 2 months
Ratio of Follicle Stimulating Hormone (FSH) to Luteinizing Hormone (LH)
2 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Lahore

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 11, 2024

Primary Completion (Actual)

November 11, 2024

Study Completion (Actual)

December 11, 2024

Study Registration Dates

First Submitted

July 31, 2025

First Submitted That Met QC Criteria

May 8, 2026

First Posted (Actual)

May 14, 2026

Study Record Updates

Last Update Posted (Actual)

May 28, 2026

Last Update Submitted That Met QC Criteria

May 22, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB-UOL-FAHS/930/2023

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Poly Cystic Ovary Syndrome

Clinical Trials on Control

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe